Just to add some context: e-bike commuters in a hilly city would go through the stock organic brake pads in <500 km sometimes. Could be as little as 6 weeks. The shop I worked at (back in the day) would replace them with longer wearing third-party pads.
I enjoy using both, but you’re leaving out microphonics (especially on zippers), cable tangle and getting frayed/damaged/caught on clothing, just to name a few.
I’m on Garmin watches as well but this line of thinking is getting old. Partner has an Apple Watch and they charge it while in the shower/getting dressed and occasionally 10-15 minutes in the evening to make sure it gets through the night. Charger is in a convenient location and it’s dead easy to drop the watch on it.
If you’re running ultras, then by all means stay on Garmin. But honestly for the day to day I’ve rarely seen it be an issue.
ETA: there’s plenty of valid reasons to prefer other watches (ANT+ compatibility being one of mine) but honestly the battery life thing is really not that bad for most users.
I had heard that in the context of absurdly high hematocrit, where they would get their heart rate up to move the (very viscous) blood around their body. No source, but doesn’t sound impossible when everyone was on EPO.
> […] it's still impossible to not have all your apps plastered on the home screen, at best in folders, is a mind boggling missing feature in iOS.
You didn’t even try looking, I just checked all the way back to iOS 14 and it was already possible. Yes, it doesn’t change your opinion, but undermines the point you’re making.
If I remember correctly, part of the goal here is to gain a bit of time while the patient gets to the ER. I’m no expert but as you seem to have alluded to, the risk profile of alteplase/tenecteplase doesn’t seem to be well suited to an autoinjector with “if in doubt, use it and call the ambulance” instructions.
Hypothetically, and just out of curiosity: if mint2 were to keep this email and it would be included as part of the evidence in a lawsuit, how would this bode for Lidl?
Pretty close. Without getting into what is “cheaper and easier”, the work you need to do to publish is a bit different from the amount of work you need to do to: identify targets, set up screening assays, screen hundreds of thousands of compounds, find/optimize a hit, set up secondary assays, optimize the lead compound, do all kinds of physchem/tox/safety studies, select an indication, test in animal models if good ones exist, try and find a suitable dose range, and put all that into a package to support a phase 1 trial. This is part what I’ve seen on the biology side of things, and it only scratches the surface of what the chemistry (small-batch synthesis and the scale-up), pharmacology, and associated people contribute.
Lots of people can synthesize and test a compound in vitro. Doing the above is another challenge because it needs to work reliably in humans.
And yes, from my understanding, universities are getting better at patenting and licensing their IP. Some even do some basic drug discovery IIRC.
Nice summary!
From my limited knowledge in case someone’s more interested. Don’t know if it’s different in oncology.
Phase 1 is pretty big on safety: sentinel dosing, then gradually increasing doses until the established max is reached or until serious side effects show up. Generally also includes PK/PD aspects: what is the half-life, how long it’s detectable in the body, does this match the modeling? How is the drug eliminated? All this is used to refine the dosing (if need be) but also provides a lot of the information needed for the safety documentation.